Healthcare Cost Trends in New Users of SGLT ‐2i, DPP ‐4i and GLP ‐1 RA for Type 2 Diabetes: An Observational Longitudinal Study
Diabetes, Obesity and Metabolism · 2026-09 · 28 (9) · 7916-7922
DOI: 10.1111/dom.70923 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 14.06.2026. Verfasst von Casey P Durand und 5 weiteren Autor:innen. Beteiligte Einrichtung: Evernorth Health Services, Evernorth Research Institute, St. Louis, Missouri, USA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Dipeptidyl-Peptidase IV Inhibitors, Sodium-Glucose Transporter 2 Inhibitors, Glucagon-Like Peptide-1 Receptor Agonists. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aims
To analyse the healthcare cost trajectories following the initiation of glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA), sodium‐glucose cotransporter‐2 inhibitor (SGLT‐2i) or dipeptidyl peptidase‐4 inhibitor (DPP‐4i) therapy in patients with type 2 diabetes. Materials and Methods We conducted a difference‐in‐difference study using member‐level claims data from a national pharmacy benefit manager. Treatment‐naïve patients were categorised into three groups based on the drug they initiated first. The first fill date in 2020 or 2021 was the index date, with a one‐year look‐back period and 2 years of follow‐up. Propensity score weighting balanced the groups. We used generalised estimating equations to analyse year‐over‐year changes in per patient per month (PPPM) costs for medical, pharmacy and total cost of care expenditures.
Results
Changes in medical costs were not statistically different across drug groups in years 1 and 2. In contrast, the increase in pharmacy costs in the first year for GLP‐1 RA was significantly higher than the other two drugs. Driven primarily by pharmacy costs, total cost of care trajectories showed similar between‐drug differences.
Conclusion
Patients with type 2 diabetes initiating on a GLP‐1 RA show significantly higher pharmacy cost patterns as compared to the DPP‐4i and SGLT‐2i groups; this higher pharmacy cost is not offset by reduced medical cost during the same period. Payers and providers should consider these cost patterns in both coverage and treatment decisions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Evernorth Health Services, Evernorth Research Institute, St. Louis, Missouri, USA.
- FastHSR, Glen Allen, Virginia, USA.
ORCID-Profile: Casey P Durand
Zitieren
APA
Durand, C. P., Eatherly, M., Yao, A., Dollear, T. J., Inneh, A., & Patel, U. (2026). Healthcare Cost Trends in New Users of SGLT ‐2i, DPP ‐4i and GLP ‐1 RA for Type 2 Diabetes: An Observational Longitudinal Study. Diabetes, Obesity and Metabolism, 28(9), 7916-7922. https://doi.org/10.1111/dom.70923
Vancouver
Durand CP, Eatherly M, Yao A, Dollear TJ, Inneh A, Patel U. Healthcare Cost Trends in New Users of SGLT ‐2i, DPP ‐4i and GLP ‐1 RA for Type 2 Diabetes: An Observational Longitudinal Study. Diabetes, Obesity and Metabolism. 2026;28(9):7916-7922. doi:10.1111/dom.70923
BibTeX
@article{Durand2026,
author = {Durand, Casey P and Eatherly, Mark and Yao, Aaron and Dollear, Timothy J and Inneh, Angela and Patel, Urvashi},
title = {Healthcare Cost Trends in New Users of SGLT ‐2i, DPP ‐4i and GLP ‐1 RA for Type 2 Diabetes: An Observational Longitudinal Study},
journal = {Diabetes, Obesity and Metabolism},
year = {2026},
volume = {28},
number = {9},
pages = {7916--7922},
doi = {10.1111/dom.70923}
}
EUVIMED